Amgen and Betta Pharmaceuticals Co., Ltd (Betta Pharma) have received the approval of relevant government authorities in China to create a joint venture between the two companies. The Hangzhou, China-based joint venture, officially launched on Sept. 26, 2013. It will operate under the name Amgen-Betta Pharmaceuticals Co., Ltd. (贝达安进制药有限公司), and will be responsible for the introduction of Amgen’s Vectibix® (panitumumab) in the Chinese market. Together, Amgen and Betta Pharma aim to quickly and efficiently deliver Vectibix® to patients in China, following regulatory approval of the medicine in China.
SCIENCE & INNOVATION09.26.2013